TARGET GROUP INC.

CBDY ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $3.9M $6.6M $3.7M $0 $0 $30.0K $0
Cost of Revenue $1.8M $2.9M $2.1M $0 $25.0K $0
Gross Profit $2.1M $3.7M $1.7M $0 $5.0K $0
Gross Margin 53.3% 56.5% 44.5% 16.7%
Operating Expenses
Research & Development
SG&A Expense $136.5K $534.7K
Operating Income $-1.4M $160.5K $1.1M $-3.4M $1.3M $-6.6M $-10.3M
Operating Margin -35.0% 2.4% 29.2% -21,866.1%
Interest Expense $38 $38 $1.4M $1.1M $985.6K $514.0K $85.6K
Pretax Income $-1.4M $160.5K $-323.7K $-4.5M $272.9K $-7.1M $-10.4M
Income Tax Expense $0 $0 $0 $0 $0 $0 $0
Net Income $-1.4M $160.5K $-323.7K $-4.5M $272.9K $-7.1M $-10.4M
Net Margin -35.0% 2.4% -8.7% -23,579.6%
EPS (Basic) $0.00 $0.00 $0.00 $-0.01 $0.00 $-0.01 $-0.03
EPS (Diluted) $0.00 $0.00 $0.00 $-0.01 $0.00 $-0.01 $-0.03
Shares Outstanding (Basic) 617.0M 617.0M 617.0M 617.0M 617.0M 595.3M 566.9M 571.1M
Shares Outstanding (Diluted) 617.0M 617.0M 727.2M 617.0M 617.0M 595.3M 566.9M 571.1M
Dividends Per Share
← Newer Page 1 of 2 Older →